Cost-effectiveness of natalizumab vs fingolimod for the...

Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden

O’Day, Ken, Meyer, Kellie, Stafkey-Mailey, Dana, Watson, Crystal
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
18
Language:
english
Journal:
Journal of Medical Economics
DOI:
10.3111/13696998.2014.991786
Date:
April, 2015
File:
PDF, 500 KB
english, 2015
Conversion to is in progress
Conversion to is failed